MX2009002308A - Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina. - Google Patents

Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina.

Info

Publication number
MX2009002308A
MX2009002308A MX2009002308A MX2009002308A MX2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A
Authority
MX
Mexico
Prior art keywords
administration
tumor cells
radiation therapy
sensitization
endothelin agonists
Prior art date
Application number
MX2009002308A
Other languages
English (en)
Spanish (es)
Inventor
Luigi Lenaz
Guru Reddy
Anil Gulati
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of MX2009002308A publication Critical patent/MX2009002308A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2285Endothelin, vasoactive intestinal contractor [VIC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2009002308A 2006-08-31 2007-08-27 Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina. MX2009002308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82419706P 2006-08-31 2006-08-31
PCT/US2007/076903 WO2008027839A1 (en) 2006-08-31 2007-08-27 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Publications (1)

Publication Number Publication Date
MX2009002308A true MX2009002308A (es) 2009-09-07

Family

ID=38920900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002308A MX2009002308A (es) 2006-08-31 2007-08-27 Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina.

Country Status (15)

Country Link
US (2) US8394757B2 (enExample)
EP (1) EP2059254B1 (enExample)
JP (1) JP5306208B2 (enExample)
KR (1) KR101547361B1 (enExample)
CN (1) CN101534852B (enExample)
BR (1) BRPI0722292A2 (enExample)
CA (1) CA2661833C (enExample)
DK (1) DK2059254T3 (enExample)
ES (1) ES2541657T3 (enExample)
IL (1) IL197335A (enExample)
MX (1) MX2009002308A (enExample)
NO (1) NO20091203L (enExample)
RU (1) RU2009111605A (enExample)
WO (1) WO2008027839A1 (enExample)
ZA (1) ZA200901425B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
EP2187948A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2010017332A2 (en) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
US10323150B2 (en) 2015-09-25 2019-06-18 Nippon Kayaku Kabushiki Kaisha Azo compound, ink composition, ink jet recording method, and colored article

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU686018B2 (en) 1994-09-20 1998-01-29 Amcor Packaging (New Zealand) Limited A container
EP0799051B1 (en) 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
WO2000018393A1 (en) * 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
GB9910155D0 (en) 1999-04-30 1999-06-30 Microbiological Research Agenc Augmented agglutination assay
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
EP1819367B1 (en) * 2004-11-22 2013-11-20 The Board Of Trustees Of The University Of Illinois Use of the endothelin etb receptor agonists irl-1620 in tumor imaging
CA2598439A1 (en) 2005-02-22 2006-08-31 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Also Published As

Publication number Publication date
KR101547361B1 (ko) 2015-08-25
ZA200901425B (en) 2010-04-28
CN101534852A (zh) 2009-09-16
CA2661833C (en) 2016-01-26
DK2059254T3 (en) 2015-07-13
US20080318846A1 (en) 2008-12-25
US8394757B2 (en) 2013-03-12
EP2059254A1 (en) 2009-05-20
JP2010502638A (ja) 2010-01-28
WO2008027839A1 (en) 2008-03-06
US20130150649A1 (en) 2013-06-13
ES2541657T3 (es) 2015-07-23
EP2059254B1 (en) 2015-04-08
KR20090069279A (ko) 2009-06-30
IL197335A (en) 2013-07-31
RU2009111605A (ru) 2010-10-10
NO20091203L (no) 2009-03-23
CN101534852B (zh) 2013-02-13
JP5306208B2 (ja) 2013-10-02
CA2661833A1 (en) 2008-03-06
BRPI0722292A2 (pt) 2014-04-15
IL197335A0 (en) 2011-08-01
US8957014B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
ZA202007440B (en) Methods for increasing efficacy of folr1 cancer therapy
MX2009004748A (es) Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.
IL197335A (en) Sensitization of cancer cells to treatment @ radioactive @ B @ Y @ agonists @ of endothelin
CA3257131A1 (en) PSMA-TARGETING COMPOUNDS AND RELATED USES
EP4559918A3 (en) Glucosylceramide synthase inhibitors
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
CL2015003285A1 (es) Arilquinazolinas
CL2012001180A1 (es) Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
NZ726666A (en) Compositions and methods of use of phorbol esters
EP2519542A4 (en) ANTI-CDH3 ANTIBODY AND ITS USE
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
WO2012064967A3 (en) Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
MX2010001263A (es) Inyeccion, solucion de inyeccion y preparacion de equipo de inyeccion.
HK1132915A (en) Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
WO2005107387A3 (en) Targeting of radioimagining and radiotherapy agents
UA57736U (ru) Способ лечения рецидивного химиорезистентного paka яичников
UA73773U (ru) Инъекционная игла-якорь для проведения секторальной резекции молочной железы
UA29770U (ru) Применение мигрепина как вещества с противоболевыми свойствами

Legal Events

Date Code Title Description
FG Grant or registration